

Andrew L Mason

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2619900/publications.pdf>

Version: 2024-02-01

154
papers

11,468
citations

38660

50
h-index

30010

103
g-index

156
all docs

156
docs citations

156
times ranked

11324
citing authors

#	ARTICLE	IF	CITATIONS
1	Sialic acid-containing glycolipids mediate binding and viral entry of SARS-CoV-2. <i>Nature Chemical Biology</i> , 2022, 18, 81-90.	3.9	141
2	Metagenomics Versus Metatranscriptomics of the Murine Gut Microbiome for Assessing Microbial Metabolism During Inflammation. <i>Frontiers in Microbiology</i> , 2022, 13, 829378.	1.5	15
3	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. <i>Journal of Hepatology</i> , 2022, 77, 84-97.	1.8	21
4	Vitamin D Is Associated with Clinical Outcomes in Patients with Primary Biliary Cholangitis. <i>Nutrients</i> , 2022, 14, 878.	1.7	8
5	Apples to Apples? A Comparison of Real-World Tolerability of Antiretrovirals in Patients with Human Immunodeficiency Virus Infection and Patients with Primary Biliary Cholangitis. <i>Viruses</i> , 2022, 14, 516.	1.5	3
6	Mass Spectrometry-Based Shotgun Glycomics Using Labeled Glycan Libraries. <i>Analytical Chemistry</i> , 2022, 94, 4997-5005.	3.2	4
7	Ethnicity, disease severity, and survival in Canadian patients with primary biliary cholangitis. <i>Hepatology</i> , 2022, 76, 303-316.	3.6	6
8	Isolation of a Human Betaretrovirus from Patients with Primary Biliary Cholangitis. <i>Viruses</i> , 2022, 14, 886.	1.5	7
9	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1688-1697.e14.	2.4	30
10	Single Topic Conference on Autoimmune Liver Disease from the Canadian Association for the Study of the Liver. <i>Canadian Liver Journal</i> , 2021, 4, 401-425.	0.3	1
11	Combination antiretroviral therapy improves recurrent primary biliary cholangitis following liver transplantation. <i>Liver International</i> , 2021, 41, 1879-1883.	1.9	9
12	An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs. <i>Journal of Hepatology</i> , 2021, 75, 572-581.	1.8	62
13	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 179-187.e6.	2.4	57
14	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 684-692.e6.	2.4	17
15	De novo and recurrent liver disease. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2020, 46-47, 101688.	1.0	1
16	Differences in HBV Replication, APOBEC3 Family Expression, and Inflammatory Cytokine Levels Between Wild-Type HBV and Pre-core (G1896A) or Basal Core Promoter (A1762T/G1764A) Mutants. <i>Frontiers in Microbiology</i> , 2020, 11, 1653.	1.5	13
17	Case report: progressive familial intrahepatic cholestasis type 3 with compound heterozygous ABCB4 variants diagnosed 15 years after liver transplantation. <i>BMC Medical Genetics</i> , 2020, 21, 238.	2.1	4
18	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. <i>American Journal of Gastroenterology</i> , 2020, 115, 1066-1074.	0.2	74

#	ARTICLE	IF	CITATIONS
19	Real-World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis. <i>Hepatology Communications</i> , 2020, 4, 1332-1345.	2.0	28
20	Seroprevalence of Human Betaretrovirus Surface Protein Antibodies in Patients with Breast Cancer and Liver Disease. <i>Journal of Oncology</i> , 2020, 2020, 1-9.	0.6	6
21	Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2295-2304.e2.	2.4	18
22	Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. <i>Journal of Hepatology</i> , 2020, 73, 559-565.	1.8	47
23	Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. <i>Gut</i> , 2020, 69, 1502-1509.	6.1	28
24	Simplified care-pathway selection for nonspecialist practice. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, Publish Ahead of Print, .	0.8	2
25	Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1127-1136.	1.9	66
26	Cirrhosis and Autoimmune Liver Disease. <i>Current Hepatology Reports</i> , 2019, 18, 49-58.	0.4	0
27	Randomized clinical trial: Combination antiretroviral therapy with tenofovir-emtricitabine and lopinavir-ritonavir in patients with primary biliary cholangitis. <i>Canadian Liver Journal</i> , 2019, 2, 31-44.	0.3	11
28	Self-reported experiences of patients living with primary biliary cholangitis (PBC): Are we treating the liver but not the patient?. <i>Canadian Liver Journal</i> , 2019, 2, 45-47.	0.3	1
29	Reply. <i>Gastroenterology</i> , 2019, 156, 2354-2355.	0.6	1
30	The Prevalence of Anti-Hexokinase-1 and Anti-Kelch-Like 12 Peptide Antibodies in Patients With Primary Biliary Cholangitis Is Similar in Europe and North America: A Large International, Multi-Center Study. <i>Frontiers in Immunology</i> , 2019, 10, 662.	2.2	21
31	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2076-2084.e2.	2.4	54
32	Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. <i>Journal of Hepatology</i> , 2019, 71, 357-365.	1.8	148
33	Fibroblast Growth Factor 2 Enhances Zika Virus Infection in Human Fetal Brain. <i>Journal of Infectious Diseases</i> , 2019, 220, 1377-1387.	1.9	23
34	Non-Invasive Prediction of High-Risk Varices in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. <i>American Journal of Gastroenterology</i> , 2019, 114, 446-452.	0.2	65
35	Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival. <i>Gastroenterology</i> , 2019, 156, 96-107.e1.	0.6	82
36	Severe vitamin D deficiency is a prognostic biomarker in autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 173-182.	1.9	46

#	ARTICLE	IF	CITATIONS
37	New perspectives on the complexity of genetic predisposition to autoimmune liver disease in indigenous Canadians. <i>Liver International</i> , 2018, 38, 789-791.	1.9	5
38	A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. <i>Hepatology</i> , 2018, 67, 1890-1902.	3.6	204
39	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. <i>American Journal of Gastroenterology</i> , 2018, 113, 254-264.	0.2	64
40	Milder disease stage in patients with primary biliary cholangitis over a 44-year period: A changing natural history. <i>Hepatology</i> , 2018, 67, 1920-1930.	3.6	55
41	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. <i>Gut</i> , 2018, 67, 1517-1524.	6.1	42
42	Human Fetal Astrocytes Infected with Zika Virus Exhibit Delayed Apoptosis and Resistance to Interferon: Implications for Persistence. <i>Viruses</i> , 2018, 10, 646.	1.5	47
43	Epidemiology and liver transplantation burden of primary biliary cholangitis: a retrospective cohort study. <i>CMAJ Open</i> , 2018, 6, E664-E670.	1.1	12
44	Is PBC a viral infectious disease?. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2018, 34-35, 27-39.	1.0	14
45	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , 2017, 152, 1975-1984.e8.	0.6	355
46	Transmission of hepatitis D virus between spouses: A longitudinal study of the first reported Canadian case. <i>IDCases</i> , 2017, 8, 37-41.	0.4	4
47	Systematic review: recurrent autoimmune liver diseases after liver transplantation. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 45, 485-500.	1.9	93
48	Recurrence of primary biliary cholangitis after liver transplantation: A Japanese perspective. <i>Hepatology Communications</i> , 2017, 1, 391-393.	2.0	8
49	Effect of Oral Capsule vs Colonoscopy-Delivered Fecal Microbiota Transplantation on Recurrent <i>Clostridium difficile</i> Infection. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1985.	3.8	446
50	Characterization of the Gut Microbiome Using 16S or Shotgun Metagenomics. <i>Frontiers in Microbiology</i> , 2016, 7, 459.	1.5	659
51	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. <i>Gut</i> , 2016, 65, 321-329.	6.1	139
52	Mucosal Barrier Depletion and Loss of Bacterial Diversity are Primary Abnormalities in Paediatric Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 462-471.	0.6	178
53	Cerebrospinal Fluid in a Small Cohort of Patients with Multiple Sclerosis Was Generally Free of Microbial DNA. <i>Frontiers in Cellular and Infection Microbiology</i> , 2016, 6, 198.	1.8	9
54	Combination antiretroviral studies for patients with primary biliary cirrhosis. <i>World Journal of Gastroenterology</i> , 2016, 22, 349.	1.4	17

#	ARTICLE	IF	CITATIONS
55	Pericentriolar Targeting of the Mouse Mammary Tumor Virus GAG Protein. <i>PLoS ONE</i> , 2015, 10, e0131515.	1.1	8
56	Time to Make the Change from "Primary Biliary Cirrhosis" to "Primary Biliary Cholangitis". <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2015, 29, 293-293.	0.8	9
57	Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid. <i>Gastroenterology</i> , 2015, 148, 751-761.e8.	0.6	470
58	Role of Novel Retroviruses in Chronic Liver Disease: Assessing the Link of Human Betaretrovirus with Primary Biliary Cirrhosis. <i>Current Infectious Disease Reports</i> , 2015, 17, 460.	1.3	13
59	Frequent proviral integration of the human betaretrovirus in biliary epithelium of patients with autoimmune and idiopathic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 393-405.	1.9	31
60	Editorial: betaretrovirus in biliary epithelia of patients with autoimmune and cryptogenic liver disease " authors" reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 41, 491-491.	1.9	1
61	Impact of combination antiretroviral therapy in the NOD.c3c4 mouse model of autoimmune biliary disease. <i>Liver International</i> , 2015, 35, 1442-1450.	1.9	19
62	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. <i>Gastroenterology</i> , 2015, 149, 1804-1812.e4.	0.6	330
63	Mitochondriome and Cholangiocellular Carcinoma. <i>PLoS ONE</i> , 2014, 9, e104694.	1.1	12
64	PR3-ANCA: A Promising Biomarker in Primary Sclerosing Cholangitis (PSC). <i>PLoS ONE</i> , 2014, 9, e112877.	1.1	57
65	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. <i>Gastroenterology</i> , 2014, 147, 1338-1349.e5.	0.6	365
66	Letter: biochemical response to combination antiretroviral therapy in patients with primary biliary cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2014, 39, 236-237.	1.9	6
67	The Genetics of Complex Cholestatic Disorders. <i>Gastroenterology</i> , 2013, 144, 1357-1374.	0.6	126
68	Systematic investigation of elevated cholestatic enzymes during the third posttransplant month. <i>Liver Transplantation</i> , 2013, 19, S23-S30.	1.3	9
69	Intrahepatic cholestasis in common chronic liver diseases. <i>European Journal of Clinical Investigation</i> , 2013, 43, 1069-1083.	1.7	49
70	Liver transplantation for overlap syndromes of autoimmune liver diseases. <i>Liver International</i> , 2013, 33, 210-219.	1.9	39
71	Is there a Role for Cyclophilin Inhibitors in the Management of Primary Biliary Cirrhosis?. <i>Viruses</i> , 2013, 5, 423-438.	1.5	5
72	Liver transplantation in hepatitis B core-negative recipients using livers from hepatitis B core-positive donors: A 13-year experience. <i>Liver Transplantation</i> , 2013, 19, 611-618.	1.3	33

#	ARTICLE	IF	CITATIONS
73	A Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection. <i>Annals of Hepatology</i> , 2013, 12, 282-293.	0.6	15
74	Canadian national retrospective chart review comparing the long term effect of cyclosporine vs. tacrolimus on clinical outcomes in patients with post-liver transplantation hepatitis C virus infection. <i>Annals of Hepatology</i> , 2013, 12, 282-293.	0.6	6
75	ImmunoChip analyses identify a novel risk locus for primary biliary cirrhosis at 13q14, multiple independent associations at four established risk loci and epistasis between 1p31 and 7q32 risk variants. <i>Human Molecular Genetics</i> , 2012, 21, 5209-5221.	1.4	139
76	Association of primary biliary cirrhosis with variants in the CLEC16A, SOCS1, SPIB and SIAE immunomodulatory genes. <i>Genes and Immunity</i> , 2012, 13, 328-335.	2.2	78
77	Incidence and risk factors associated with <i>de novo</i> autoimmune hepatitis after liver transplantation. <i>Liver International</i> , 2012, 32, 1426-1433.	1.9	42
78	Mouse Mammary Tumor Virus in Human Breast Cancer. <i>American Journal of Pathology</i> , 2011, 179, 1588-1590.	1.9	41
79	The evidence supports a viral aetiology for primary biliary cirrhosis. <i>Journal of Hepatology</i> , 2011, 54, 1312-1314.	1.8	32
80	Mouse mammary tumor virus in anti-mitochondrial antibody producing mouse models. <i>Journal of Hepatology</i> , 2011, 55, 876-884.	1.8	32
81	The Impact of Sirolimus on hepatitis C Recurrence after Liver Transplantation. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2011, 25, 28-34.	1.8	42
82	Lessons Learned from Liver Transplantation with the Canadian First Nations. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2011, 25, 305-306.	1.8	3
83	Cyclosporine A inhibits in vitro replication of betaretrovirus associated with primary biliary cirrhosis. <i>Liver International</i> , 2010, 30, 871-877.	1.9	22
84	Linking human beta retrovirus infection with primary biliary cirrhosis. <i>Gastroenterologie Clinique Et Biologique</i> , 2010, 34, 359-366.	0.9	21
85	Cyclosporine A Protects Against Primary Biliary Cirrhosis Recurrence After Liver Transplantation. <i>American Journal of Transplantation</i> , 2010, 10, 852-858.	2.6	79
86	Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. <i>Nature Genetics</i> , 2010, 42, 658-660.	9.4	389
87	Variants at IRF5-TNPO3, 17q12-21 and MMEL1 are associated with primary biliary cirrhosis. <i>Nature Genetics</i> , 2010, 42, 655-657.	9.4	205
88	Mouse retroviruses and chronic fatigue syndrome: Does X (or P) mark the spot?. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 15666-15667.	3.3	13
89	A Shorter Duration of Pre-Transplant Abstinence Predicts Problem Drinking After Liver Transplantation. <i>American Journal of Gastroenterology</i> , 2009, 104, 1700-1706.	0.2	89
90	Risk factors for recurrence of autoimmune hepatitis after liver transplantation. <i>Liver Transplantation</i> , 2009, 15, 1254-1261.	1.3	117

#	ARTICLE	IF	CITATIONS
91	The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. <i>Liver International</i> , 2009, 29, 169-174.	1.9	40
92	Duplication of MER115 on chromosome 4 in patients with primary biliary cirrhosis. <i>Liver International</i> , 2009, 29, 375-383.	1.9	8
93	Primary biliary cirrhosis, bacteria and molecular mimicry: what's the molecule and where's the mimic?. <i>Liver International</i> , 2009, 29, 779-782.	1.9	16
94	Immunogenetic susceptibility to diabetes mellitus in patients with liver disease. <i>Liver International</i> , 2009, 29, 1543-1551.	1.9	6
95	Primary Biliary Cirrhosis Associated with <i>HLA, IL12A</i> , and <i>IL12RB2</i> Variants. <i>New England Journal of Medicine</i> , 2009, 360, 2544-2555.	13.9	569
96	Isolation of a human betaretrovirus resembling mouse mammary tumor virus (MMTV) from patients with primary biliary cirrhosis. <i>Retrovirology</i> , 2009, 6, P55.	0.9	3
97	Novel Approaches to Immunosuppression in Liver Transplantation. , 2009, , 19-44.		0
98	Metagenomics and the case of the deadly hamster. <i>Hepatology</i> , 2008, 48, 679-683.	3.6	2
99	Clinical trial: randomized controlled study of zidovudine and lamivudine for patients with primary biliary cirrhosis stabilized on ursodiol. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 886-894.	1.9	52
100	Other Potential Medical Therapies: The Use of Antiviral Agents to Investigate and Treat Primary Biliary Cirrhosis. <i>Clinics in Liver Disease</i> , 2008, 12, 445-460.	1.0	15
101	De Novo Sirolimus-Based Immunosuppression After Liver Transplantation for Hepatocellular Carcinoma: Long-Term Outcomes and Side Effects. <i>Transplantation</i> , 2007, 83, 1162-1168.	0.5	165
102	New insights from recurrent primary biliary cirrhosis in liver transplantation: The paradox of BEComing a fibroblast?. <i>Hepatology</i> , 2007, 45, 837-840.	3.6	6
103	Quality of life and everyday activities in patients with primary biliary cirrhosis. <i>Hepatology</i> , 2007, 46, 1836-1843.	3.6	30
104	Reverse transcriptase activity in patients with primary biliary cirrhosis and other autoimmune liver disorders. <i>Alimentary Pharmacology and Therapeutics</i> , 2007, 26, 587-595.	1.9	24
105	An autoimmune biliary disease mouse model for primary biliary cirrhosis: Something for everyone. <i>Hepatology</i> , 2006, 44, 1047-1050.	3.6	16
106	The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. <i>Cell Metabolism</i> , 2006, 3, 321-331.	7.2	558
107	Recurrent Hepatitis C Post-Transplantation: Where Are We Now and Where Do We Go From Here? A Report from the Canadian Transplant Hepatology Workshop. <i>Canadian Journal of Gastroenterology & Hepatology</i> , 2006, 20, 725-734.	1.8	5
108	Role of viral replication in extrahepatic syndromes related to hepatitis B virus infection. <i>Minerva Gastroenterologica E Dietologica</i> , 2006, 52, 53-66.	2.2	15

#	ARTICLE	IF	CITATIONS
109	Hepatitis B Virus Replication in Damaged Endothelial Tissues of Patients with Extrahepatic Disease. American Journal of Gastroenterology, 2005, 100, 972-976.	0.2	57
110	Pilot Studies of Single and Combination Antiretroviral Therapy in Patients with Primary Biliary Cirrhosis. American Journal of Gastroenterology, 2004, 99, 2348-2355.	0.2	57
111	Proof of Principal Studies to Assess the Role of the Human Betaretrovirus in Patients with Primary Biliary Cirrhosis. American Journal of Gastroenterology, 2004, 99, 2499-2500.	0.2	16
112	Primary biliary cirrhosis: Report of a focus study group. Hepatology, 2004, 40, 1013-1020.	3.6	29
113	Cloning the human betaretrovirus proviral genome from patients with primary biliary cirrhosis. Hepatology, 2004, 39, 151-156.	3.6	104
114	Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transplantation, 2004, 10, 1301-1311.	1.3	241
115	Patients with primary biliary cirrhosis make anti-viral and anti-mitochondrial antibodies to mouse mammary tumor virus. Gastroenterology, 2004, 127, 1863-1864.	0.6	27
116	Primary biliary cirrhosis: Report of a focus study group. Hepatology, 2004, 40, 1013-1020.	3.6	9
117	Treatment of recurrent hepatitis C in liver transplant recipients: Is there any histologic benefit?. Liver Transplantation, 2003, 9, 354-359.	1.3	19
118	Does lamivudine prophylaxis eradicate persistent HBV DNA from allografts derived from anti-HBc-positive donors?. Liver Transplantation, 2003, 9, 1258-1264.	1.3	27
119	Is type II diabetes another extrahepatic manifestation of HCV infection?. American Journal of Gastroenterology, 2003, 98, 243-246.	0.2	20
120	Does a betaretrovirus infection trigger primary biliary cirrhosis?. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 8454-8459.	3.3	225
121	Acute autoimmune hepatitis presenting with centrilobular liver disease: case report and review of the literature. American Journal of Gastroenterology, 2002, 97, 2670-2673.	0.2	74
122	Biologic effects of anti-retroviral therapy in patients with primary biliary cirrhosis. Journal of Hepatology, 2002, 36, 154.	1.8	0
123	Primary biliary cirrhosis: New thoughts on pathophysiology and treatment. Current Gastroenterology Reports, 2002, 4, 45-51.	1.1	27
124	Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis?. Hepatology, 2002, 36, 150-155.	3.6	306
125	Pilot study of lamivudine for patients with primary biliary cirrhosis. Journal of Hepatology, 2001, 34, 205.	1.8	3
126	Steroid-free immunosuppression through thymoglobulin induction in liver transplantation. Transplantation Proceedings, 2001, 33, 1470-1471.	0.3	24

#	ARTICLE	IF	CITATIONS
127	AUTOIMMUNE LIVER DISEASE. Clinics in Liver Disease, 2001, 5, 287-314.	1.0	30
128	Viral Induction of Type 2 Diabetes and Autoimmune Liver Disease. Journal of Nutrition, 2001, 131, 2805S-2808S.	1.3	15
129	Steroid-free liver transplantation using rabbit antithymocyte globulin induction: Results of a prospective randomized trial. Liver Transplantation, 2001, 7, 693-697.	1.3	123
130	Transplantation of livers from HBc Ab positive donors into HBc Ab negative recipients: a strategy and preliminary results. Clinical Transplantation, 2001, 15, 55-58.	0.8	36
131	Viruses and diabetes: is there something sweet about hepatitis C infection?. Ochsner Journal, 2001, 3, 158-63.	0.5	4
132	GP73, a novel Golgi-localized protein upregulated by viral infection. Gene, 2000, 249, 53-65.	1.0	226
133	Tt Virus: Will Work for Food?. American Journal of Gastroenterology, 1999, 94, 3398-3401.	0.2	0
134	Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology, 1999, 29, 328-333.	3.6	593
135	Hepatic manifestations of familial patent ductus venosus in adults. Gut, 1999, 45, 442-445.	6.1	43
136	Retroviruses in autoimmune liver disease: genetic or environmental agents?. Archivum Immunologiae Et Therapiae Experimentalis, 1999, 47, 289-97.	1.0	15
137	Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology, 1998, 27, 1736-1742.	3.6	198
138	Detection of retroviral antibodies in primary biliary cirrhosis. Lancet, The, 1998, 352, 739-740.	6.3	6
139	Expression of pyruvate-dehydrogenase complex PDC-E2 on biliary epithelial cells induced by lymph nodes from primary biliary cirrhosis. Lancet, The, 1998, 352, 1595-1596.	6.3	57
140	HERV-K10s and Immune-Mediated (Type 1) Diabetes. Cell, 1998, 95, 14-16.	13.5	38
141	Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. Lancet, The, 1998, 351, 1620-1624.	6.3	154
142	A case of syncytial giant cell hepatitis with features of a paramyxoviral infection. American Journal of Gastroenterology, 1998, 93, 1931-1937.	0.2	45
143	Co-existence of hepatitis A and adult Reye's syndrome.. Gut, 1997, 41, 121-124.	6.1	13
144	Hepatitis and cholestasis in a middle-aged woman. Hepatology, 1996, 24, 730-734.	3.6	22

#	ARTICLE	IF	CITATIONS
145	The A to Z of new hepatotropic agents: Human hepatitis viruses and monkey business. Liver Transplantation, 1996, 2, 395-405.	1.9	6
146	Hepatitis and cholestasis in a middle-aged woman. Hepatology, 1996, 24, 730-734.	3.6	2
147	What Causes Fulminant Hepatic Failure of Unknown Etiology?. American Journal of Clinical Pathology, 1995, 104, 491-494.	0.4	13
148	Genomic variations in the hepatitis B core gene: A possible factor influencing response to interferon alfa treatment. Gastroenterology, 1995, 108, 505-514.	0.6	65
149	Hepatitis B virus replication in diverse cell types during chronic hepatitis B virus infection. Hepatology, 1993, 18, 781-789.	3.6	169
150	Intractable neurological Wilson's disease treated with orthotopic liver transplantation. Digestive Diseases and Sciences, 1993, 38, 1746-1750.	1.1	51
151	Hepatitis B and Liver Transplantation – Problems and Promises. New England Journal of Medicine, 1993, 329, 1885-1887.	13.9	39
152	Increased hepatocyte expression of hepatitis B virus transcription in patients with features of fibrosing cholestatic hepatitis. Gastroenterology, 1993, 105, 237-244.	0.6	66
153	Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen. Gastroenterology, 1992, 103, 1649-1656.	0.6	132
154	Hepatitis B virus DNA in peripheral-blood mononuclear cells in chronic hepatitis B after HBsAg clearance. Hepatology, 1992, 16, 36-41.	3.6	93